TickerFacts.

Scinai Immunotherapeutics Ltd. (SCNI): Shareholders' Equity

Annual figures by period end, from SEC filings.

$8.10M
As of 2025-12-31
$9.98M2021-12-31: $982.0K2022-12-31: -$1.76M2023-12-31: -$4.57M2024-12-31: $9.98M2025-12-31: $8.10M$8.10M
2021-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$8.10M-18.8%2026-04-01, Balance as of period end
2024-12-31$9.98Mn/m2026-04-01, Balance as of period end
2023-12-31-$4.57Mn/m2026-04-01, Balance as of period end
2022-12-31-$1.76Mn/m2025-05-07, Balance as of period end
2021-12-31$982.0Kn/a2024-05-15, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Scinai Immunotherapeutics Ltd. (SCNI)2025-12-31$8.10M-18.8%
Inhibrx Biosciences, Inc. (INBX)2025-12-31$7.99M-94.0%
Outlook Therapeutics, Inc. (OTLK)2025-09-30-$32.19Mn/m
Pluri Inc. (PLUR)2026-06-30-$23.04Mn/m
Prokidney Corp. (PROK)2025-12-31-$1.01Bn/m
Humacyte, Inc. (HUMA)2025-12-31$3.11Mn/m
ImageneBio, Inc. (IMA)2025-12-31$133.14Mn/m
Aligos Therapeutics, Inc. (ALGS)2025-12-31$53.55Mn/m
Cardiff Oncology, Inc. (CRDF)2025-12-31$45.39M-45.3%

Compare SCNI, INBX, OTLK, PLUR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗